Quantcast

Latest Rhinitis Stories

2008-09-23 03:00:27

BRIDGEWATER, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today the U.S. Food and Drug Administration (FDA) has approved Nasacort AQ Nasal Spray (triamcinolone acetonide) for children aged 2-5 years old for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis. The FDA based its approval on the results of a multicenter, randomized, double-blind, placebo-controlled study demonstrating that Nasacort AQ can be used safely and effectively...

2008-09-19 21:00:11

A COMMON painkiller may be one of the key driving forces behind the worldwide epidemic of childhood asthma, reveals a major study today. Researchers who analysed data on more than 200,000 children found strong links between paracetamol use and both the development of asthma and the symptoms' appearance. Taking paracetamol once a month more than tripled the chances of six and seven-year-olds suffering wheezing attacks. The drug was also associated with an increased risk of...

2008-09-10 06:00:08

OXFORD, England, September 10 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, today announced positive results from a phase II clinical study of its anti-allergy technology, ToleroMune(R), in the field of cat allergy. The trial showed that ToleroMune treatment can substantially reduce allergic reactions to the allergen that causes most cat allergies, and importantly was well tolerated by all patients. Circassia conducted...

2008-09-03 00:00:24

An allergy educational group has named Greensboro, N.C., as the most challenging place to live for people with seasonal allergies. Greenville, S.C., Little Rock, Ark., Raleigh-Durham, N.C., and Jackson, Miss., rounded out the top five on the list compiled by the Asthma and Allergy Foundation of America. The group said fall brings new allergy triggers that are not prevalent in the spring, such as ragweed. "During the fall when outdoor allergy triggers peak, people may continue to suffer...

2008-09-02 09:00:07

Orexo, a Swedish pharmaceutical company, has initiated a Phase II program for the product OX914, a new candidate for the treatment of inflammatory airway diseases including asthma, chronic obstructive pulmonary disease and rhinitis. The patients will be treated with OX914 in a disease model for inflammatory airway disease. Approximately 36 patients with seasonal allergic rhinitis will be given placebo or OX914 in doses of 15 or 50mg for two weeks in a double-blind three-way cross-over...

2008-08-27 15:01:10

ANTONY, France, August 27 /PRNewswire-FirstCall/ -- - Oralair(R) Grasses 300IR Highly Positive Clinical Results in a Pharmacodynamic Study Conducted in an Allergen Challenge Chamber Stallergenes S.A. announces the highly positive results of a new study conducted in an Allergen Challenge Chamber (ACC). The study on Oralair(R) Grasses included 86 adult patients exposed to grass pollen challenge with different treatment durations: 1 week, 1 month, 2 and 4 months without a titration phase....

2008-08-27 03:00:24

By Anonymous Doctors usually tell parents of a newborn not to introduce solid foods until the baby is at least four to six months old, ostensibly to lessen the chances that the infant will develop atopic diseases - asthma, allergic rhinitis (runny nose), eczema, and food and inhalant sensitization - later on in life. In a recent study that was published in the January 2008 issue of Pediatrics, researchers in Germany looked into whether delaying the introduction of solids past four or six...

2008-08-19 09:00:16

KENILWORTH, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that ASMANEX(R) TWISTHALER(R) 110 mcg (mometasone furoate inhalation powder) is now available in pharmacies nationwide. ASMANEX is indicated for the maintenance treatment of asthma as prophylactic therapy in patients four years of age and older, and is the first and only once-daily inhaled corticosteroid inhaler approved for this use in children as young as 4. ASMANEX was approved for children...

2008-08-05 12:01:07

Meda has submitted the registration application to the FDA for azelastine nasal spray in the new formulation with extra strength. The application seeks approval to treat symptoms of seasonal allergic rhinitis and perennial allergic rhinitis. The new formulation is patent pending. Six Phase III studies evaluating efficacy and safety and long term safety have been conducted involving about 1,600 patients treated with azelastine extra strength. The higher strength has been shown to offer...

2008-08-04 03:00:32

Regulatory News: Meda AB (STO:MEDAA): The registration application for azelastine nasal spray in the new formulation with Extra Strength has been submitted to the US Food and Drug Administration (FDA), seeking approval to treat symptoms of Seasonal Allergic Rhinitis and Perennial Allergic Rhinitis. The new formulation is patent pending. Six phase III studies evaluating efficacy and safety and a long term safety have been conducted involving about 1,600 patients treated with...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'